2Asist. Dr., Prof. Dr. Reşat N. Belger Beyoğlu Göz Eğitim ve Araştırma Hastanesi, İstanbul, Türkiye
3Doç. Dr., Prof. Dr. Reşat N. Belger Beyoğlu Göz Eğitim ve Araştırma Hastanesi, İstanbul, Türkiye
4Prof. Dr., Prof. Dr. Reşat N. Belger Beyoğlu Göz Eğitim ve Araştırma Hastanesi, İstanbul, Türkiye Purpose: To present long-term results of intravitreal ranibizumab (IVR) treatment of myopic choroidal neovascular membrane (CNVM).
Material and Method: Thirty-three eyes of 33 patients with CNVM secondary to pathologic myopia were included in this retrospective study. All the cases had IVR (0.5 mg/0.05 ml) injection under sterile condition. Best-corrected visual acuity (BCVA), anterior-posterior segment exam with slit-lamp biomicroscopy, color fundus photo, fundus fl uorescein angiography (FFA), and spectral optical coherence tomography (SOCT) were performed at baseline. IVR injection was repeated when there was intraretinal/subretinal fl uid existence in SOCT scans and (or) leakage on FFA scans and (or) visual acuity was decreased.
Results: The mean age was 53.8±15 years (range: 25-88 years). The mean follow-up time was 24 months. The mean BCVA was 1.1±0.31 log- MAR before the injection. The mean increase in BCVA at month 12 was 0.14±0.3 (p=0.04) logMAR, and at month 24 it was 0.10±0.4 (p=0.17) logMAR. The mean central macular thickness (CMT) was 479±104 ?m at baseline and change to 361±85 ?m (p<0.001) at month 3, 411±95 at month 12, and 371±76 ?m at month 24. The mean injection count was 2.5 at first year and 0.5 at second year of follow-up. In the %61 (19 eyes) of the cases, there was no need for injection at all in the second year. There was no complication related the treatment.
Conclusion: IVR treatment seems safe and effective to treatment of CNVM secondary to pathologic myopia. Injection counts decreases at the second year.
Keywords : Pathologic myopia, choroidal neovascular membrane, ranibizumab